

# Global Health Emergencies: Role of Laboratory Medicine

**Shannon Hader, MD, MPH**  
**Director, Division of Global HIV/AIDS**  
**Center for Global Health**  
**Centers for Disease Control and Prevention**  
**Atlanta, GA**

CDC, Atlanta, Georgia

Center for Global Health  
International Lab Branch



# Outline

- PEPFAR as a Global Health Emergency
- Gaps in Diagnostics
- Access to Diagnostics
- Impact of Diagnostics and Role of Clinicians
- Need for key Partnerships

# Where we were before PEPFAR...

1991 – 2001:

**Peak**  
of the  
**Pandemic**




- **2001:** Nearly 10,000 new HIV infections daily
- **2002:** 50,000 on treatment in sub-Saharan Africa
- Health systems overwhelmed by the epidemic
- Life expectancy declines of over 20 years in some countries
- Loss of working age population – reversing decades of development progress
- Stigma and discrimination were pervasive

# CDC PEPFAR-Supported Countries

## Initial PEPFAR 10 Year Goals:

- Treatment for at least 6 million people
- Prevention of 12 million new infections
- Care for 12 million, including 5 million orphans and vulnerable children
- Training of at least 140,000 new health care workers in HIV/AIDS



■ Countries with HIV/AIDS program offices (N=41)

■ Additional countries receiving HIV/AIDS support (N=37)

# Celebrating PEPFAR's Remarkable Success

Since its launch in 2003,

PEPFAR has saved millions of lives\*

- **7.7 M people** on life-saving ART
- More than **one million babies** born HIV-free (*>240,000 infant infections averted in 2014*)
- **6.5 M men** received VMMC services
- **17 M people** received care and support, including **5 M orphans and vulnerable children**
- **21 M people** in priority and key populations reached with prevention interventions

The U.S. government has committed **more than \$52 billion** to bilateral HIV/AIDS programs, the Global Fund, and bilateral TB programs since 2004.

Under the Obama  
Administration,  
**unprecedented  
progress**


has been made, building on the  
strong foundation laid under the  
Bush Administration.

How much more can we  
achieve

**together?**


Is it possible to control the  
pandemic while ensuring  
no one is left behind?

# Number Of HIV-Infected Adults And Children Receiving Antiretroviral Therapy



# Dramatic Impact of PEPFAR on Life Expectancy In Countries Significantly Impacted by HIV/AIDS

Life Expectancy at Birth (in years), 1960-2013; Select Countries



# PEPFAR's Evolution

## From Emergency Response to Sustainable Impact for an AIDS-free Generation

### 2003 – 2007: PEPFAR I

- Emergency response
- Delivering prevention, care, & treatment services
- Building & strengthening health systems to deliver HIV services



### 2008 – 2012: PEPFAR 2

- Shift from emergency to sustainable response
- Shared responsibility & country-driven programs
- Scaling up core interventions (ART, PMTCT & VMMC) for impact



### 2013-2018: PEPFAR 3

- Sustainability & shared responsibility
- Quality, oversight, transparency, & accountability for impact
- Accelerating core interventions for epidemic control




# Progress is Unequal : Decline in New HIV Infections Varies By Country

Percent Change in Number of New HIV Infections,  
Select Countries, 2005 - 2013



# The Diagnostics Gaps to Meet the UNAIDS 90-90-90 goals




Source: R Peeling , 2014

1


# Gaps in Diagnostics

# Lab Costs as a Proportion of Treatment and Care Costs




Source: UNAIDS 2013


# Access to Diagnostics in the Treatment Cascade



# HIV Testing Offered In PEPFAR-Supported Countries Between 2004-2013



# Proportion of Individual Never Tested for HIV



Source: Demographic and Health Surveys

# HIV Rapid Testing Sites



# Published Reports of Misdiagnosis

OPEN ACCESS Freely available online

2009 

## The Evaluation of a Rapid *In Situ* HIV Confirmation Test in a Programme with a High Failure Rate of the WHO HIV Two-Test Diagnostic Algorithm

OPEN ACCESS Freely available online

2013 

Boeras *et al.* *Journal of the International AIDS Society* 2011, 14:18  
<http://www.jiasociety.org/content/14/1/18>



JOURNAL OF  
THE INTERNATIONAL  
AIDS SOCIETY

imited  
HIV

RESEARCH

EXPERT  
REVIEWS

## Causes of false-positive HIV rapid diagnostic test results

*Expert Rev. Anti Infect. Ther.* 12(1), 49–62 (2014)

Indeter  
results  
centres

Debrah I Boeras<sup>1</sup>,  
Elwyn Chomba<sup>6</sup>,  
Angela M Calien

Derryck Klarkowski<sup>1</sup>,  
Daniel P O'Brien<sup>2,3</sup>,  
Leslie Shanks<sup>1</sup> and  
Kasha P Singh<sup>4,5</sup>

HIV rapid diagnostic tests have enabled widespread implementation of HIV programs in resource-limited settings. If the tests used in the diagnostic algorithm are susceptible to the same cause for false positivity, a false-positive diagnosis may result in devastating consequences. In resource-limited settings, the lack of routine confirmatory testing, compounded by incorrect interpretation of weak positive test lines and use of tie-breaker

# Accuracy of Test Results is Critical - Quality Assurance Cycle



# Tools Developed by WHO and Partners to Support Reliable HIV Related Point of Care Testing

2010

A Handbook for Improving HIV Testing and Counselling Services

Field-test ver

Handbook for Improving the Quality of HIV-related Point-of-Care Testing:  
*Ensuring Reliability and Accuracy of Test Results*

QA Cycle for Implementing POCT

**PHASE III: Evaluate, Improve, and Sustain**  
1. Post-market surveillance  
2. Use monitoring data for decision making  
3. Advocacy and communication of best practices  
4. Encourage social entrepreneurship and public-private partnerships  
5. Increase country ownership  
6. Operational research



**PHASE I: Planning Quality Improvement for HIV-related POCT**  
1. Engage leadership  
2. Establish the national QA/POCT coordination team  
3. Define roles and responsibilities  
4. Develop or review policies & incorporate QA into national plan  
5. Define standards for quality for POCT  
6. Conduct situational analysis  
7. Develop and implement plan  
8. Plan financial and human resources  
9. Selection and assessment of sites  
10. Selection of product

**PHASE II: Implementation of Quality Assurance for POCT**  
1. Improve training and ensure certification of all POCT testers  
2. Site supervision and certification  
3. Implement QA Process Control  
4. Strengthen and innovate QA-related documentation  
5. Strengthen supply chain for QA




World Health Organization

Framework for the Development of HIV-Related Point of Care Testing Policy for Implementation and Quality Assurance


Ensuring Reliable and Accurate Test Results

# Rapid Testing Quality Improvement Initiative (RTQII)

- \$40 million OGAC-funded initiative for 2 years
- Target 7 PMTCT Option B+ countries
- Promote critical QA elements and completion of QA cycle



# Predicted Viral Load Needs



● Global Viral Load forecast


● Global Viral Load need

Source: Clinton Health Access Initiative, 2013

# Capacity for CD4 and Viral Load Testing

<b>Geographical region</b> (number of countries surveyed = 97)	Number of responding countries	<b>CD4</b>	<b>Viral load</b>
		Average number of people receiving antiretroviral therapy per laboratory [range]	Average number of people receiving antiretroviral therapy per laboratory [range]
Sub-Saharan Africa	20	2 287 [10-10 745]	39 539 [5257-326 241]
Middle East and North Africa	8	150 [15-439]	183 [15-531]
East, South and South-East Asia and Oceania	12	897 [23-5350]	5 125 [256-55 686]
Europe and Central Asia	4	1 025 [309-1419]	1 025 [523-1419]
Latin America and the Caribbean	22	1 913 [61-5843]	2 773 [156-20 042]

# Infant HIV Testing: PEPFAR APR Data 2013



A large, bold, brown number '2' is positioned on the left side of the slide. It is the first character of the title 'Access and Coverage'.

# **Access and Coverage**

Diagnostics

Access


Impact of Treatment Cascade



+



=



Quality

Incidence

Rapid Test  
CD4  
Viral Load

Uptake  
Coverage

Quality of  
Treatment  
Prevention  
Cascade

# Factors Influencing Access

- Role of Point of Care Testing
- Policy
- Funders
- Public Private Partnerships
- Laboratory health systems and networks


# Strengthening Sample Transport Networks - Uganda

- Initial pilot of 19 hubs reached 625 health facilities.

- Scaled up to 60 hubs serving 1700 health facilities launched.



# Sample Transport Costs For DBS Decreased By 62% After Setting Up The Sample Referral System



A large, stylized, light blue number '3' is positioned on the left side of the slide, partially overlapping the text. The number is composed of two thick, curved segments.

# **Impact and Role of Clinicians**

# Country X: Example Of The CD4 PIMA Point of Care Utilization, 2012

• Total number of sites

269

• Sites with “0” consumption

46

• Sites with consumption  $\leq 1/\text{day}$

91


• % of sites with 0 or consuming  $\leq 1/\text{day}$

34%

• % of sites with access to referral lab


30%

# Many Tests are Performed but Results are Never Delivered to Patients



# Role of Clinicians - TB Treatment Initiation

Even when Xpert MTB/RIF is available, many patients treated empirically



# 4 Key Partnerships

# Key Partnerships to Improve Access to Diagnostics

Clinicians

Policy

Program managers

Implementing partners

Donors

Multi-laterals

# Power of Partnership - Public Private Partnerships are Critical for increasing Access to Quality Diagnostics

U.S. President's Emergency Plan for AIDS Relief



## SUPPORT for COUNTRIES

Activities will be implemented through three primary means:

- Country-specific laboratory strengthening programs that offer PEPFAR and

### New Public-Private Partnership to Strengthen Laboratory Systems

In a pioneering public-private partnership, the U.S. President's Emergency Plan for AIDS Relief (Emergency Plan/PEPFAR) and BD (Becton, Dickinson and Company) will support the improved services in African countries severely affected by tuberculosis (TB).

Through this five-year, public-private partnership, the Emergency Plan and BD will work with laboratories, Ministries of Health, and other partners to improve TB diagnostic services.

### Building Tanzania's laboratory capacity through public-private partnership



Christina MWANGI\*, Christy WISTARI\*, Kenneth LEMA\*, Charles MASSAMBU\*, Ralph TIMPERI\*, Vincent MGAYA\*, Jeffery MINTON\*, Scott KREITLEIN\*  
 \*CDC Tanzania \*Abbott Fund Tanzania \*Ministry of Health and Social Welfare \*Association of Public Health Laboratories \*Design 4 Others



#### State of many health laboratories in Tanzania



#### Nationwide Modernisation of 23 Regional Laboratories in Tanzania



#### Regional laboratory modernised by Abbott Fund in 2007



# Conclusions

- ❑ Remarkable progress in scaling up HIV prevention and treatment programs
- ❑ Laboratory services and access to diagnostics critical in achieving AIDS-free generation and UNAIDS 90-90-90 goals
  - Quality central to expanding diagnostics
  - Strategies needed to scale – up viral load testing
- ❑ Key partnerships central to achieve access to diagnostics
- ❑ Central role of clinicians



# Thanks!

**For more information please contact Centers for Disease Control and Prevention**

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: [cdcinfo@cdc.gov](mailto:cdcinfo@cdc.gov) Web: [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Center for Global Health  
Division of Global HIV/AIDS

